Q4 2025 Catalyst Pharmaceuticals Inc Earnings Call Transcript

Feb 26, 2026 / 01:30 PM GMT

Release Date Price: €20.44 (+1.24%)

Transcript 10-K

Key Points

Positve

Catalyst Pharmaceuticals Inc (CPRX) reported a 19.8% year-over-year revenue growth in 2025, reaching $589 million, exceeding their guidance range.
The company's flagship product, FApps, achieved a 17% increase in revenue, highlighting strong market penetration and patient identification efforts.
Agamri, a differentiated corticosteroid for Duchenne muscular dystrophy, saw a remarkable 154.3% year-over-year growth, with revenues reaching $117.1 million.
Catalyst Pharmaceuticals Inc (CPRX) has a strong cash position, ending 2025 with $709.2 million in cash and cash equivalents, providing financial flexibility for future initiatives.
The company is actively pursuing business development opportunities, conducting over 100 assessments in 2025, with a focus on expanding their rare disease portfolio.

Negative

Phi Kappa faced a decline in revenue due to generic competition, with 2026 sales forecasted to drop significantly to between $40 million and $45 million.
The company is experiencing increased SG&A expenses, primarily due to higher employee compensation and consulting fees related to business initiatives.
Catalyst Pharmaceuticals Inc (CPRX) anticipates continued revenue erosion for Phi Kappa due to increased generic competition.
The company faces ongoing litigation with Hetero USA, with a trial set for March 2026, posing potential legal and financial risks.
The impact of the Inflation Reduction Act (IRA) is expected to increase annually, affecting the company's Medicare Part D net product revenue.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

CPRX.OQ - Catalyst Pharmaceuticals Inc
Q4 2025 Catalyst Pharmaceuticals Inc Earnings Call
Feb 26, 2026 / 01:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good morning and thank you for standing by. My name is John and I will be your conference operator today. At this time, I would like to welcome everyone to the Catalyst Pharmaceuticals 4th quarter in full year 2025 financial results conference call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer session.

If you would like to ask a question during this time, simply press star, followed by the number one on your telephone keypad, and to withdraw your question, simply press one again. I would now like to turn the conference over to Mike Culb, Chief Financial Officer. Please go ahead.

------------------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.